✦ LIBER ✦

P92 Docetaxel versus epirubicin/cyclophosphamide (EC)as first-line therapy in metastatic breast cancer (MBC): results from the randomized phase II TIPP study

✍ Scribed by M. Friedrich; C. Wasemann; S. Tauchert; A. Ertan; W. Schmidt; K. Diedrich

Book ID: 114315815
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 160 KB
Volume: 14
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(05)80128-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II Randomized Crossover Study of

A Phase II Randomized Crossover Study of Liposomal Doxorubicin Versus Weekly Docetaxel in the First-line Treatment of Women With Metastatic Breast Cancer

✍ Denise A. Yardley; Howard A. Burris III; David R. Spigel; Bobby L. Clark; Elizab 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 359 KB

Concomitant versus sequential administra

Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma : Results from the Gruppo Oncologico Nord Ovest Randomized Trial

✍ Pier Franco Conte; Valentina Guarneri; Paolo Bruzzi; Tiziana Prochilo; Barbara S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract ## BACKGROUND The authors performed a randomized trial comprising patients with metastatic breast carcinoma (MBC). They used a noninferiority design to evaluate whether the results of sequential administration of epirubicin and paclitaxel were not markedly worse than the concomitant ad

5075 POSTER Non-pegylated Liposomal Doxo

5075 POSTER Non-pegylated Liposomal Doxorubicin (Myocet e) Plus Docetaxel (Taxotere e) (MYTAX), as First-line Chemotherapy (CHT), in Metastatic Breast Cancer (MBC): Results of a Phase II Study

✍ Imperatori, L.; Lippe, P.; Trapuzzano, C.; Laid, G.; Cappelletti, C.; Tamburrano 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

406 POSTER Safety and efficacy of suniti

406 POSTER Safety and efficacy of sunitinib malate (SU11248) as second-line therapy in metastatic breast cancer (MBC) patients: preliminary results from a phase II study

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 262 KB

Capecitabine plus paclitaxel versus epir

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group

✍ Hans-Joachim Lück, Andreas Du Bois, Sibylle Loibl, Iris Schrader, Jens Huober, V 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 279 KB

413 POSTER A multicenter phase II study

413 POSTER A multicenter phase II study of Epirubicin (E) with low-dose herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary results

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 134 KB